(Q36847271)

16 August 2017

1 reference

title

Management of the behavioral aspects of Parkinson's disease (English)

1 reference

16 August 2017

1 reference

3

Joseph H Friedman

1 reference

16 August 2017

Leora L Borek

1

1 reference

16 August 2017

Kelvin L Chou

series ordinal

2

1 reference

16 August 2017

language of work or name

1 reference

1 June 2007

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

16 August 2017

published in

1 reference

16 August 2017

volume

7

1 reference

16 August 2017

issue

6

1 reference

16 August 2017

page(s)

711-725

1 reference

The occurrence of depression in Parkinson's disease. A community-based study.

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Non-recognition of depression and other non-motor symptoms in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Depression in Parkinson's disease: a quantitative and qualitative analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Altered serotonin metabolism in depressed patients with parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

The neuropathologic basis of different clinical subgroups of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Effect of subthalamic stimulation on mood state in Parkinson's disease: evaluation of previous facts and problems

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Effect of age at onset on frequency of depression in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

What contributes to quality of life in patients with Parkinson's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

The quality of life in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Antidepressant studies in Parkinson's disease: a review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Citalopram treatment of depression in Parkinson's disease: the impact on anxiety, disability, and cognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

The SSRI, citalopram, improves bradykinesia in patients with Parkinson's disease treated with L-dopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

SSRIs do not worsen Parkinson's disease: evidence from an open-label, prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Sertraline for the treatment of depression in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Escitalopram for major depression in Parkinson's disease: an open-label, flexible-dosage study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

SSRIs in the treatment of depression in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Risk of serious extrapyramidal symptoms in patients with Parkinson's disease receiving antidepressant drugs: a pharmacoepidemiologic study comparing serotonin reuptake inhibitors and other antidepressant drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression: effect on quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Bupropion in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Does Nefazodone Improve Both Depression and Parkinson Disease? A Pilot Randomized Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

S-Adenosyl-Methionine improves depression in patients with Parkinson's disease in an open-label clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Mirtazapine in Parkinsonian tremor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Test characteristics of the 15-item geriatric depression scale and Hamilton depression rating scale in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Dose-response relationship of levodopa with mood and anxiety in fluctuating Parkinson's disease: a double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Affective symptoms in multiple system atrophy and Parkinson's disease: response to levodopa therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Cognitive-behavioral treatment for social phobia in Parkinson's disease: A single-case study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Prospective study of hallucinations and delusions in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Hallucinosis in idiopathic Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instruments

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Clozapine-responsive tremor in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Diabetes mellitus among parkinsonian patients treated chronically with clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Risperidone for hallucinations in levodopa-treated Parkinson's disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Olanzapine treatment for dopaminergic-induced hallucinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Use of ziprasidone in parkinsonian patients with psychosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Treatment of drug-induced psychosis in Parkinson's disease with ziprasidone can induce severe dose-dependent off-periods and pathological laughing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Ziprasidone and psychosis in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Rivastigmine for dementia associated with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

A systematic review of prevalence studies of dementia in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Risk and incidence of dementia in a cohort of older subjects with Parkinson's disease in the United Kingdom.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Parkinson's disease and apolipoprotein E: possible association with dementia but not age at onset

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Are Parkinson's disease with dementia and dementia with Lewy bodies the same entity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Neuropathologic evidence that the Lewy body variant of Alzheimer disease represents coexistence of Alzheimer disease and idiopathic Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Delirium: optimising management

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Delirium in Parkinson's disease patients. a five-year follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

A community-based study of sleep disorders in patients with Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

ABC of sleep disorders. Sleep and sleep problems in elderly people

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Quetiapine for insomnia in Parkinson disease: results from an open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Melatonin for sleep disturbances in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Sleep breathing disorders in patients with idiopathic Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Symposium: Normal and abnormal REM sleep regulation: REM sleep behaviour disorder: an update on a series of 96 patients and a review of the world literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Phenomenology of dreams in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Rapid eye movement sleep behaviour disorder: demographic, clinical and laboratory findings in 93 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Update on the pharmacology of REM sleep behavior disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Dream phenomena induced by chronic levodopa therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Excessive daytime sleepiness in Parkinson disease: is it the drugs or the disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Excessive daytime sleepiness and sleep benefit in Parkinson's disease: a community-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Daytime sleepiness and other sleep disorders in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Measurement properties and hierarchical item structure of the Epworth Sleepiness Scale in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Exacerbated physical fatigue and mental fatigue in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Fatigue in Parkinson's disease: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Diurnal effects of motor activity and fatigue in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Fatigue in patients with Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Clinical problems in non-fluctuating patients with Parkinson's disease: a community-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Assessment of sleepiness and unintended sleep in Parkinson's disease patients taking dopamine agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Frequency of 'chronic active Epstein-Barr virus infection' in a general medical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Chronic fatigue in primary care. Prevalence, patient characteristics, and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

The Parkinson fatigue scale.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Effects of fatigue on physical activity and function in patients with Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Can the brain be protected through exercise? Lessons from an animal model of parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Treadmill training ameliorates dopamine loss but not behavioral deficits in hemi-parkinsonian rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Neuroprotective effects of prior limb use in 6-hydroxydopamine-treated rats: possible role of GDNF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Fatigue in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Adjunctive atomoxetine for residual fatigue in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Apathy: a neuropsychiatric syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

21 January 2018

Apathy is not depression

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Dissociating apathy and depression in Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Apathy in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Clinical, neuropsychological, and morphometric correlates of apathy in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Range of neuropsychiatric disturbances in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Does subthalamic nucleus stimulation induce apathy in Parkinson's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Family, Alzheimer's disease and negative symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Methylphenidate treats apathy in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Treatment of pseudobulbar laughter after gamma knife thalamotomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Pseudobulbar crying induced by stimulation in the region of the subthalamic nucleus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Stimulation of the subthalamic nucleus in Parkinson's disease: a 5 year follow up

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Pathologic gambling in Parkinson's disease: a behavioral manifestation of pharmacologic treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Impulse control disorders in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Pathologic gambling in patients with restless legs syndrome treated with dopaminergic agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Pathological gambling associated with dopamine agonist therapy in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Disabling repetitive behaviors in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Treatment of pathological crying with citalopram

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

Prognosis of Parkinson Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.6.711

21 January 2018

Identifiers

DOI

10.1586/14737175.7.6.711

1 reference

16 August 2017

1 reference